Medicine and Dentistry
Autologous Stem Cell Transplantation
16%
DNA
6%
Drug Megadose
16%
Extracellular Trap
6%
Hypercoagulability
13%
Lenalidomide
33%
Light Chain
14%
Melphalan
16%
Membrane Microparticle
6%
Monoclonal Gammopathy of Undetermined Significance
33%
Multiple Myeloma
90%
Nephropathy
33%
Neutrophil
6%
Overall Survival
23%
Phospholipid
10%
Procoagulant
13%
Progression Free Survival
13%
Renal Failure
9%
Thrombin
6%
Thromboplastin
10%
Keyphrases
Calibrated Automated Thrombogram
6%
Carfilzomib
33%
Cast Nephropathy
33%
Clinical High Risk
5%
Daratumumab
66%
Deep Reduction
9%
Dialysis-dependent Renal Failure
9%
Immunomodulatory Drugs (IMiDs)
13%
Line of Therapy
13%
Median Time
11%
Monotherapy
8%
Multiple Myeloma
5%
Multiple Myeloma Patients
33%
Overall Response Rate
5%
Phenotypical Analysis
6%
Real-world Outcomes
33%
Standard Risk
5%
Time to Next Treatment
13%
Tissue Factor Expression
33%
Treatment Timing
5%
Uninvolved Immunoglobulins
12%
Worse Outcome
5%
Immunology and Microbiology
Blood Clotting
11%
CD38
5%
Cyclophosphamide
5%
Daratumumab
66%
Dexamethasone
5%
Drug Megadose
5%
Immunoglobulin A
5%
Intravenous Immunoglobulin
5%
Multiple Myeloma
100%
Overall Survival
33%
Plasma Cell
5%
Progression Free Survival
33%
Thrombin
5%
Tissue Factor
33%
Transmission Electron Microscopy
5%
Ultracentrifugation
5%
Western Blot
5%
